Percutaneous pulmonary valve implantation: Present status and evolving future

Mohammad M. Ansari, Rhanderson Cardoso, Daniel Garcia, Satinder K Sandhu, Eric Horlick, Derek Brinster, Giuseppe Martucci, Nicolo Piazza

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Due to recurrent right ventricular outflow tract (RVOT) dysfunction, patients with complex congenital heart disease of the RVOT traditionally require multiple surgical interventions during their lifetimes. Percutaneous pulmonary valve implantation (PPVI) has been developed as a nonsurgical alternative for the treatment of right ventricular to pulmonary artery stenosis or pulmonary regurgitation. PPVI has been shown to be a safe and effective procedure in patients with dysfunctional surgical RVOT conduits. In this population, PPVI has the potential to improve symptoms, functional capacity, and biventricular hemodynamics. However, limitations to the anatomical substrate and size of the RVOT currently restrict PPVI eligibility to less than one-quarter of patients with RVOT dysfunction. The current review discusses contemporary practices in PPVI, evidence supporting the procedure, and future technologies and developments in the field.

Original languageEnglish (US)
Pages (from-to)2246-2255
Number of pages10
JournalJournal of the American College of Cardiology
Volume66
Issue number20
DOIs
StatePublished - Nov 17 2015

Fingerprint

Pulmonary Valve
Patient Rights
Pulmonary Valve Insufficiency
Heart Diseases
Hemodynamics
Technology
Population

Keywords

  • congenital heart disease
  • outcome assessment (health care)
  • pulmonary regurgitation
  • right ventricular outflow tract dysfunction
  • transcatheter pulmonary valve

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Percutaneous pulmonary valve implantation : Present status and evolving future. / Ansari, Mohammad M.; Cardoso, Rhanderson; Garcia, Daniel; Sandhu, Satinder K; Horlick, Eric; Brinster, Derek; Martucci, Giuseppe; Piazza, Nicolo.

In: Journal of the American College of Cardiology, Vol. 66, No. 20, 17.11.2015, p. 2246-2255.

Research output: Contribution to journalArticle

Ansari, MM, Cardoso, R, Garcia, D, Sandhu, SK, Horlick, E, Brinster, D, Martucci, G & Piazza, N 2015, 'Percutaneous pulmonary valve implantation: Present status and evolving future', Journal of the American College of Cardiology, vol. 66, no. 20, pp. 2246-2255. https://doi.org/10.1016/j.jacc.2015.09.055
Ansari, Mohammad M. ; Cardoso, Rhanderson ; Garcia, Daniel ; Sandhu, Satinder K ; Horlick, Eric ; Brinster, Derek ; Martucci, Giuseppe ; Piazza, Nicolo. / Percutaneous pulmonary valve implantation : Present status and evolving future. In: Journal of the American College of Cardiology. 2015 ; Vol. 66, No. 20. pp. 2246-2255.
@article{d95e4ba964e24fbd86c0ba403c0725eb,
title = "Percutaneous pulmonary valve implantation: Present status and evolving future",
abstract = "Due to recurrent right ventricular outflow tract (RVOT) dysfunction, patients with complex congenital heart disease of the RVOT traditionally require multiple surgical interventions during their lifetimes. Percutaneous pulmonary valve implantation (PPVI) has been developed as a nonsurgical alternative for the treatment of right ventricular to pulmonary artery stenosis or pulmonary regurgitation. PPVI has been shown to be a safe and effective procedure in patients with dysfunctional surgical RVOT conduits. In this population, PPVI has the potential to improve symptoms, functional capacity, and biventricular hemodynamics. However, limitations to the anatomical substrate and size of the RVOT currently restrict PPVI eligibility to less than one-quarter of patients with RVOT dysfunction. The current review discusses contemporary practices in PPVI, evidence supporting the procedure, and future technologies and developments in the field.",
keywords = "congenital heart disease, outcome assessment (health care), pulmonary regurgitation, right ventricular outflow tract dysfunction, transcatheter pulmonary valve",
author = "Ansari, {Mohammad M.} and Rhanderson Cardoso and Daniel Garcia and Sandhu, {Satinder K} and Eric Horlick and Derek Brinster and Giuseppe Martucci and Nicolo Piazza",
year = "2015",
month = "11",
day = "17",
doi = "10.1016/j.jacc.2015.09.055",
language = "English (US)",
volume = "66",
pages = "2246--2255",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "20",

}

TY - JOUR

T1 - Percutaneous pulmonary valve implantation

T2 - Present status and evolving future

AU - Ansari, Mohammad M.

AU - Cardoso, Rhanderson

AU - Garcia, Daniel

AU - Sandhu, Satinder K

AU - Horlick, Eric

AU - Brinster, Derek

AU - Martucci, Giuseppe

AU - Piazza, Nicolo

PY - 2015/11/17

Y1 - 2015/11/17

N2 - Due to recurrent right ventricular outflow tract (RVOT) dysfunction, patients with complex congenital heart disease of the RVOT traditionally require multiple surgical interventions during their lifetimes. Percutaneous pulmonary valve implantation (PPVI) has been developed as a nonsurgical alternative for the treatment of right ventricular to pulmonary artery stenosis or pulmonary regurgitation. PPVI has been shown to be a safe and effective procedure in patients with dysfunctional surgical RVOT conduits. In this population, PPVI has the potential to improve symptoms, functional capacity, and biventricular hemodynamics. However, limitations to the anatomical substrate and size of the RVOT currently restrict PPVI eligibility to less than one-quarter of patients with RVOT dysfunction. The current review discusses contemporary practices in PPVI, evidence supporting the procedure, and future technologies and developments in the field.

AB - Due to recurrent right ventricular outflow tract (RVOT) dysfunction, patients with complex congenital heart disease of the RVOT traditionally require multiple surgical interventions during their lifetimes. Percutaneous pulmonary valve implantation (PPVI) has been developed as a nonsurgical alternative for the treatment of right ventricular to pulmonary artery stenosis or pulmonary regurgitation. PPVI has been shown to be a safe and effective procedure in patients with dysfunctional surgical RVOT conduits. In this population, PPVI has the potential to improve symptoms, functional capacity, and biventricular hemodynamics. However, limitations to the anatomical substrate and size of the RVOT currently restrict PPVI eligibility to less than one-quarter of patients with RVOT dysfunction. The current review discusses contemporary practices in PPVI, evidence supporting the procedure, and future technologies and developments in the field.

KW - congenital heart disease

KW - outcome assessment (health care)

KW - pulmonary regurgitation

KW - right ventricular outflow tract dysfunction

KW - transcatheter pulmonary valve

UR - http://www.scopus.com/inward/record.url?scp=84946811811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946811811&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2015.09.055

DO - 10.1016/j.jacc.2015.09.055

M3 - Article

C2 - 26564602

AN - SCOPUS:84946811811

VL - 66

SP - 2246

EP - 2255

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 20

ER -